CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Echinacea purpurea +1 morebiological
Likely dose
Echinacea purpurea 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00860795
NCT00860795N/ACompleted
CompareCT.gov

Study of the Immunologic Effects of Echinacea Purpurea in Adults

University of Washington·interventional·Posted Mar 12, 2009·Updated May 1, 2018

In Brief

A clinical study evaluating Echinacea purpurea and placebo for Upper Respiratory Tract Infections. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The goal of this study is to determine if Echinacea purpurea stimulates the immune system. For the study, 20 healthy adults will be randomized to receive Echinacea purpurea or placebo for 10 days. Blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. It is postulated that adults receiving the Echinacea will have evidence of immune stimulation and those receiving placebo will not.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Respiratory Tract Infections
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 12, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.3 years ago

Interventions

Echinacea purpureabiological

Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days

placebodrug

placebo 25 ml daily in 2 divided doses for 10 days